



EHA2023 abstracts: What's hot in AML?

To help navigate the exciting content being presented at the EHA2023 Congress, the AML Hub Steering Committee have provided their recommendations for the top abstracts to look out for in AML.



Click
the abstracts
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://aml-hub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

Oral abstract sessions and poster presentations

Friday, June 9

Abstract	Type	Title	Presenter
S130	Oral presentation	<u>Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed <i>FLT3</i>-ITD wild-type AML</u>	Pau Montesinos
S132	Oral presentation	<u>Updated results of VEN-A-QUI study: a phase 1-2 trial to assess the safety and efficacy of triplets for newly diagnosed unfit AML patients: azacitidine or low-dose cytarabine with venetoclax and quizartinib</u>	Juan Miguel Bergua Burgues
S133	Oral presentation	<u>An entirely oral regimen of oral-ATO, ATRA and ascorbic acid in risk-adapted treatment of newly-diagnosed APL resulted in excellent clinical/molecular responses with durable remission</u>	Harry Gill
S134	Oral presentation	<u>FLAG-IDA combined with gemtuzumab ozogamicin (GO) reduced MRD levels and improved overall survival in <i>NPM1</i>mut AML independent of <i>FLT3</i> and MRD status, results from the AML19 trial</u>	Nigel Russell
P491	Poster presentation	<u>Day 14 measurable residual disease assessment predicts treatment outcomes in patients with acute myeloid leukemia treated with intensive chemotherapy - results of the PALG-AML1/2016 study</u>	Agnieszka Wierzbowska
P494	Poster presentation	<u>A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia</u>	Anthony Selwyn Stein
P497	Poster presentation	<u>Clinical outcomes of <i>NPM1</i>-mutated acute myeloid leukemia (AML) patients with measurable residual disease (MRD) relapse after achievement of a first MRD-negative remission</u>	Madlen Jentzsch
P525	Poster presentation	<u>Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HM therapies</u>	Keith Pratz
P554	Poster presentation	<u>Results of a randomized placebo-controlled phase 2 study of hypomethylating agents with or without eltrombopag in elderly AML patients (DELTA)</u>	Katja Sockel
P555	Poster presentation	<u>Olutasidenib in post-venetoclax patients with mutant <i>IDH1</i> AML</u>	Jorge Cortes
P567	Poster presentation	<u>Phase 1b omniverse trial: safety and tolerability of oral azacitidine in combination with venetoclax for treatment of acute myeloid leukemia</u>	Shaun Fleming

Oral abstract sessions and poster presentations

Saturday, June 10

Abstract	Type	Title	Presenter
S248	Oral presentation	<u>SIERRA trial results with a targeted radiotherapy, lomab-B, a myeloablative conditioning with reduced intensity tolerability yields high CR, long term survival in HSCT ineligible active R/R AML</u>	Boglarka Gyurkocza
S310	Oral presentation	<u>Venetoclax plus azacitidine delays deterioration of health-related quality of life in patients with acute myeloid leukemia: VIALE-A long-term follow up</u>	Keith Pratz

Oral abstract sessions and poster presentations

Sunday, June 11

Abstract	Type	Title	Presenter
LB2711	Late breaking oral presentation	<u>BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for <i>FLT3</i>-ITD AML</u>	—
LB2713	Late breaking oral presentation	<u>Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory <i>NPM1</i>-mutated AML</u>	—
S137	Oral presentation	<u>Impact of allogeneic hematopoietic cell transplantation in first complete remission plus FLT3 inhibition with quizartinib in acute myeloid leukemia with <i>FLT3</i>-ITD: results from QuANTUM-First</u>	Richard Schlenk
S138	Oral presentation	<u>Validation of the revised 2022 European LeukemiaNet (ELN) risk stratification in adult patients with acute myeloid leukemia</u>	Marius Bill



Follow us on Twitter to keep up to date
with the latest from the EHA2023 Congress!

@AML_Hub
#EHA2023
aml-hub.com